Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP003385)
SBP Name	Fab Ranibizumab
Synonyms	Ranibizumab; Lucentis
Design Method	Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status	Marketed
SBP Sequence	>VH Chain EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTY AADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVT VSS >VL Chain DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK

Protein Scaffold Information of This SBP
Scaffold ID	PS034 Scaffold Info	[1]
Scaffold Name	Fab
Scaffold Class	Antibody fragment
Fold Type	Beta-Sheets + Loops

Binding Target(s) of This SBP (BTS)

BTS Name	Details	Mechanism	Application	Affinity	Research Organization	Ref
Vascular endothelial growth factor A	BTS Info	Inhibitor	Choroidal neovascularisation [ICD-11: 9B76]; Degenerative high myopia [ICD-11: 9B76]; Diabetic macular oedema [ICD-11: 9B71.02]; Retinal oedema [ICD-11: 9B78.7]; Age related macular degeneration [ICD-11: 9B75.0Z]; Diabetic retinopathy [ICD-11: 9B71.0]; Retinopathy of prematurity [ICD-11: 9B71.3]; Polypoidal choroidal vasculopathy [ICD-11: 9B75.Y]	N.A.	Carolina Retina Center PA; Xbrane	[1]

Clinical Trial Information of This SBP
NCT00056823	Click to show the Detail
Indication	Age-Related Maculopathy
Phase	Phase I; Phase II
Title	Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)
Status	Completed
Sponsor	Genentech Inc
NCT00056836	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase III
Title	A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration
Status	Completed
Sponsor	Genentech Inc
NCT00061594	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase III
Title	A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
Status	Completed
Sponsor	Genentech Inc
NCT00089765	Click to show the Detail
Indication	Von Hippel-Lindau Syndrome
Phase	Phase I
Title	Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
Status	Completed
Sponsor	National Eye Institute (NEI)
NCT00090623	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase III
Title	A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
Status	Completed
Sponsor	Genentech Inc
NCT00095433	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase III
Title	Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
Status	Completed
Sponsor	Genentech Inc
NCT00251459	Click to show the Detail
Indication	Choroidal Neovascularization; Age-related Macular Degeneration
Phase	Phase III
Title	A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Status	Completed
Sponsor	Genentech Inc
NCT00275821	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase III
Title	Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Status	Completed
Sponsor	Novartis
NCT00284050	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II
Title	Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement
Status	Completed
Sponsor	Novartis
NCT00284089	Click to show the Detail
Indication	Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration
Phase	Phase I; Phase II
Title	Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status	Completed
Sponsor	Novartis
NCT00288561	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase II
Title	Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration
Status	Completed
Sponsor	Novartis
NCT00331864	Click to show the Detail
Indication	Age Related Macular Degeneration; Choroidal Neovascularization
Phase	Phase III
Title	SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Status	Completed
Sponsor	Novartis
NCT00344227	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase II
Title	Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
Status	Completed
Sponsor	University of Miami
NCT00363168	Click to show the Detail
Indication	Choroidal Neovascularization
Phase	Phase I
Title	Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
Status	Completed
Sponsor	Johns Hopkins University
NCT00373659	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase II
Title	An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD
Status	Completed
Sponsor	University of Miami
NCT00378196	Click to show the Detail
Indication	Telangiectasia
Phase	Phase I
Title	Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial
Status	Completed
Sponsor	Johns Hopkins University
NCT00379795	Click to show the Detail
Indication	Choroidal Neovascularization, Age-related Macular Degeneration
Phase	Not Applicable
Title	An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO
Status	Completed
Sponsor	Genentech Inc
NCT00384449	Click to show the Detail
Indication	Eales' Disease
Phase	Phase II; Phase III
Title	Lucentis (Ranibizumab) for Eales' Disease
Status	Completed
Sponsor	Oregon Health and Science University
NCT00387582	Click to show the Detail
Indication	Diabetic Retinopathy; Diabetic Macular Edema
Phase	Phase II
Title	Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema
Status	Completed
Sponsor	Rocky Mountain Retina Consultants
NCT00390208	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase II
Title	Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
Status	Completed
Sponsor	Bay Area Retina Associates
NCT00395057	Click to show the Detail
Indication	Choroid Neovascularization; Age-related Macular Degeneration
Phase	Phase II
Title	A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
Status	Terminated
Sponsor	Allergan
NCT00395551	Click to show the Detail
Indication	Choroidal Neovascularization
Phase	Phase I
Title	Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.
Status	Completed
Sponsor	Ophthalmic Consultants of Boston
NCT00395707	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase I; Phase II
Title	Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
Status	Completed
Sponsor	The National Retina Institute
NCT00403039	Click to show the Detail
Indication	Retinal Vein Occlusion
Phase	Phase I
Title	Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema
Status	Completed
Sponsor	Vitreous -Retina- Macula Consultants of New York
NCT00403156	Click to show the Detail
Indication	Choroidal Neovascularization
Phase	Phase I
Title	Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Status	Withdrawn
Sponsor	Vitreous -Retina- Macula Consultants of New York
NCT00403325	Click to show the Detail
Indication	Central Serous Chorioretinopathy
Phase	Phase I
Title	Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
Status	Completed
Sponsor	Vitreous -Retina- Macula Consultants of New York
NCT00406471	Click to show the Detail
Indication	Ischemic Central Retinal Vein Occlusion
Phase	Phase I
Title	Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion
Status	Completed
Sponsor	Greater Houston Retina Research
NCT00406796	Click to show the Detail
Indication	Central Retinal Vein Occlusion
Phase	Phase I
Title	Lucentis for Central Retinal Vein Occlusion (CRVO)
Status	Completed
Sponsor	California Retina Consultants
NCT00407355	Click to show the Detail
Indication	Macular Edema; Retinal Vein Occlusion
Phase	Phase I; Phase II
Title	Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions
Status	Completed
Sponsor	Peter A Campochiaro, MD
NCT00407381	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II
Title	The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study
Status	Completed
Sponsor	Johns Hopkins University
NCT00413829	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase II
Title	Immediate Effects of Lucentis in Conjunction With Photodynamic Therapy With Visudyne in Exudative AMD(IECOMB)
Status	Completed
Sponsor	University Hospital Inselspital, Berne
NCT00417703	Click to show the Detail
Indication	Choroidal Neovascularization
Phase	.
Title	Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab
Status	Completed
Sponsor	Oklahoma State University Center for Health Sciences
NCT00423189	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase IV
Title	Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
Status	Terminated
Sponsor	David M. Brown, M.D.
NCT00424710	Click to show the Detail
Indication	Polypoidal Choroidal Vasculopathy
Phase	Phase I
Title	Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)
Status	Completed
Sponsor	Hawaii Pacific Health
NCT00429962	Click to show the Detail
Indication	Choroidal Neovascularization; Age-related Macular Degeneration
Phase	Phase III
Title	Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV
Status	Completed
Sponsor	University Hospital, Basel, Switzerland
NCT00433017	Click to show the Detail
Indication	Macular Degeneration; Choroidal Neovascularization
Phase	Phase II; Phase III
Title	Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
Status	Terminated
Sponsor	Novartis
NCT00436553	Click to show the Detail
Indication	Macular Degeneration; Choroidal Neovascularization
Phase	Phase III
Title	Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
Status	Completed
Sponsor	Novartis
NCT00440609	Click to show the Detail
Indication	Clinically Significant Diabetic Macular Edema
Phase	Phase I; Phase II
Title	Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema
Status	Completed
Sponsor	Philip J. ferrone, M.D.
NCT00444600	Click to show the Detail
Indication	Diabetic Retinopathy; Diabetic Macular Edema
Phase	Phase III
Title	Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema
Status	Completed
Sponsor	Jaeb Center for Health Research
NCT00445003	Click to show the Detail
Indication	Proliferative Diabetic Retinopathy; Diabetic Macular Edema
Phase	Phase III
Title	Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Status	Completed
Sponsor	Jaeb Center for Health Research
NCT00454389	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase III
Title	A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration
Status	Unknown
Sponsor	NeoVista
NCT00455871	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Not Applicable
Title	Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD
Status	Unknown
Sponsor	Barnes Retina Institute
NCT00456495	Click to show the Detail
Indication	Conjunctival Neoplasms
Phase	Phase I
Title	Effect of Ranibizumab on Malignant Conjunctival Neoplasia
Status	Completed
Sponsor	The New York Eye Cancer Center
NCT00457067	Click to show the Detail
Indication	Telangiectasia
Phase	Phase I
Title	Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation
Status	Completed
Sponsor	National Eye Institute (NEI)
NCT00457145	Click to show the Detail
Indication	Telangiectasia
Phase	Phase I
Title	Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation
Status	Completed
Sponsor	National Eye Institute (NEI)
NCT00457678	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase II
Title	Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself
Status	Withdrawn
Sponsor	Vitreous -Retina- Macula Consultants of New York
NCT00464581	Click to show the Detail
Indication	Cystoid Macular Edema
Phase	.
Title	Lucentis for Treatment of Macular Edema
Status	Completed
Sponsor	Retina Institute of Hawaii
NCT00467935	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase I; Phase II
Title	Scotoma Reduction in AMD Patients Treated With Ranibizumab
Status	Completed
Sponsor	Retina Research Foundation
NCT00469352	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase III
Title	A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
Status	Completed
Sponsor	Oregon Health and Science University
NCT00470678	Click to show the Detail
Indication	Choroidal Neovascularization; Age-related Macular Degeneration
Phase	Phase III
Title	EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Status	Completed
Sponsor	Novartis
NCT00470977	Click to show the Detail
Indication	Coats' Disease; Idiopathic Retinal Telangiectasia; Retinal Angiomatous Proliferation; Polypoidal Choroidal Vasculopathy; Pseudoxanthoma Elasticum; Pathological Myopia; Multi-focal Choroiditis; Rubeosis Iridis; Von Hippel Lindau Disease; BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
Phase	Phase I; Phase II
Title	Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
Status	Completed
Sponsor	Manhattan Eye, Ear & Throat Hospital
NCT00473330	Click to show the Detail
Indication	Diabetes Mellitus; Macular Edema
Phase	Phase III
Title	A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)
Status	Completed
Sponsor	Genentech Inc
NCT00473382	Click to show the Detail
Indication	Diabetes Mellitus; Macular Edema
Phase	Phase III
Title	A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)
Status	Completed
Sponsor	Genentech Inc
NCT00473642	Click to show the Detail
Indication	Age-Related Maculopathy; Choroidal Neovascularization
Phase	Phase IV
Title	Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
Status	Completed
Sponsor	Oklahoma State University Center for Health Sciences
NCT00474695	Click to show the Detail
Indication	Age-Related Maculopathy
Phase	.
Title	Study Evaluating Genotypes Using Lucentis
Status	Terminated
Sponsor	University of Utah
NCT00485836	Click to show the Detail
Indication	Macular Edema; Retinal Vein Occlusion
Phase	Phase III
Title	A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)
Status	Completed
Sponsor	Genentech Inc
NCT00486018	Click to show the Detail
Indication	Macular Edema; Retinal Vein Occlusion
Phase	Phase III
Title	A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)
Status	Completed
Sponsor	Genentech Inc
NCT00492284	Click to show the Detail
Indication	Choroidal Neovascularization; Macular Degeneration
Phase	Phase II
Title	Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
Status	Completed
Sponsor	QLT Inc
NCT00498355	Click to show the Detail
Indication	Uveitis; Cytoid Macular Edema
Phase	Phase I; Phase II
Title	Lucentis for Inflammatory Macular Edema Trial
Status	Completed
Sponsor	University of California, San Francisco
NCT00499590	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase III
Title	Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD
Status	Terminated
Sponsor	OPKO Health Inc
NCT00500344	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase I
Title	CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography
Status	Completed
Sponsor	Washington University School of Medicine
NCT00504400	Click to show the Detail
Indication	Type 2 Idiopathic Macular Telangiectasia
Phase	Phase II
Title	Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)
Status	Completed
Sponsor	University Hospital, Bonn
NCT00504959	Click to show the Detail
Indication	Subfoveal Choroidal Neovascularization (CNV); Secondary to Age-related Macular Degeneration
Phase	Phase IV
Title	Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status	Completed
Sponsor	Novartis
NCT00509795	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase III
Title	Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
Status	Completed
Sponsor	Regeneron Pharmaceuticals
NCT00510965	Click to show the Detail
Indication	Choroidal Neovascularization
Phase	Phase II
Title	Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)
Status	Completed
Sponsor	University Hospital, Bonn
NCT00511706	Click to show the Detail
Indication	Choroidal Neovascularization; Age-Related Maculopathy
Phase	Phase II
Title	Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
Status	Completed
Sponsor	Allergan
NCT00516464	Click to show the Detail
Indication	Proliferative Diabetic Retinopathy
Phase	Phase III
Title	Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy
Status	Unknown
Sponsor	Retina Associates, Kansas City
NCT00517010	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase I
Title	Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration
Status	Completed
Sponsor	University of California, Davis
NCT00527475	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase II
Title	Ranibizumab and Reduced Fluence PDT for AMD
Status	Completed
Sponsor	Texas Retina Associates
NCT00533520	Click to show the Detail
Indication	Macular Degeneration; Choroidal Neovascularization
Phase	Phase IV
Title	Evaluation of Dosing Interval of Higher Doses of Ranibizumab
Status	Completed
Sponsor	Brandon G. Busbee, MD
NCT00533689	Click to show the Detail
Indication	Electrophysiology
Phase	Phase III
Title	Study of the Long-Term Effect of Frequent Anti-VEGF Dosing on Retinal Function in Patients With Neovascular AMD
Status	Unknown
Sponsor	Tel-Aviv Sourasky Medical Center
NCT00538538	Click to show the Detail
Indication	Retinal Hemorrhage; Macular Degeneration
Phase	Phase I
Title	Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)
Status	Withdrawn
Sponsor	William Beaumont Hospitals
NCT00539734	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Not Applicable
Title	Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Status	Completed
Sponsor	Prince of Songkla University
NCT00540930	Click to show the Detail
Indication	Uveal Melanoma; Radiation Retinopathy; Radiation Maculopathy
Phase	Phase IV
Title	Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy
Status	Unknown
Sponsor	Shields, Shields and Associates
NCT00545870	Click to show the Detail
Indication	Diabetic Retinopathy; Diabetic Macular Edema; Proliferative Diabetic Retinopathy
Phase	Phase III
Title	Bevacizumab Versus Ranibizumab for Diabetic Retinopathy
Status	Completed
Sponsor	Ursula Schmidt-Erfurth, M.D.
NCT00546936	Click to show the Detail
Indication	Presumed Ocular Histoplasmosis (POHS)
Phase	Phase II
Title	Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis
Status	Unknown
Sponsor	Barnes Retina Institute
NCT00557791	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase III
Title	Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)
Status	Withdrawn
Sponsor	OPKO Health Inc
NCT00559715	Click to show the Detail
Indication	Age-related Neovascular Macular Degeneration
Phase	Phase III
Title	Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab
Status	Unknown
Sponsor	Klinikum Bremen-Mitte, gGmbH
NCT00561834	Click to show the Detail
Indication	Nonarteritic Anterior Ischemic Optic Neuropathy
Phase	Phase I
Title	Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy
Status	Completed
Sponsor	University of Colorado, Denver
NCT00562406	Click to show the Detail
Indication	Macular Edema
Phase	Not Applicable
Title	Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)
Status	Completed
Sponsor	Klinikum Ludwigshafen
NCT00567697	Click to show the Detail
Indication	Central Retinal Vein Occlusion; Macular Edema
Phase	Phase III
Title	A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO
Status	Completed
Sponsor	Aleris Helse
NCT00570193	Click to show the Detail
Indication	Choroidal Neovascularization; Macular Degeneration
Phase	Phase I; Phase II
Title	Photodynamic and Pharmacologic Treatment of CNV
Status	Completed
Sponsor	Mid-Atlantic Retina Consultations Inc
NCT00570726	Click to show the Detail
Indication	Glaucoma, Open-Angle; Failing Bleb Following Trabeculectomy
Phase	Phase I
Title	Treatment of Failing Blebs With Ranibizumab
Status	Completed
Sponsor	The New York Eye & Ear Infirmary
NCT00574093	Click to show the Detail
Indication	Neovascular Age Related Macular Degeneration
Phase	Phase II
Title	Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD
Status	Completed
Sponsor	Fondazione G.B. Bietti, IRCCS
NCT00590694	Click to show the Detail
Indication	Age-related Macular Degeneration; Pigment Epithelial Detachment; Neovascular Macular Degeneration; Wet Macular Degeneration
Phase	Phase II; Phase III
Title	Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
Status	Completed
Sponsor	Pacific Eye Associates
NCT00593450	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase III
Title	Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
Status	Completed
Sponsor	University of Pennsylvania
NCT00599222	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase III
Title	The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study
Status	Completed
Sponsor	Anders Kvanta
NCT00605943	Click to show the Detail
Indication	Macular Degeneration
Phase	.
Title	Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab
Status	Completed
Sponsor	National Eye Institute (NEI)
NCT00606138	Click to show the Detail
Indication	Proliferative Diabetic Retinopathy
Phase	Phase I; Phase II
Title	Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
Status	Completed
Sponsor	Rush University Medical Center
NCT00618644	Click to show the Detail
Indication	Sickle Cell Anemia; Retinopathy
Phase	Not Applicable
Title	Ranibizumab for Neovascularization in Sickle Cell Retinopathy
Status	Withdrawn
Sponsor	Kresge Eye Institute
NCT00626782	Click to show the Detail
Indication	Glaucoma
Phase	Phase II; Phase III
Title	Lucentis Versus Mitomycin C During Glaucoma Surgery
Status	Completed
Sponsor	Wills Eye
NCT00637377	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase III
Title	Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
Status	Completed
Sponsor	Bayer
NCT00640640	Click to show the Detail
Indication	Neovascular Age Related Macular Degeneration
Phase	Not Applicable
Title	The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)
Status	Unknown
Sponsor	Sheba Medical Center
NCT00644280	Click to show the Detail
Indication	Glaucoma
Phase	Not Applicable
Title	Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery
Status	Terminated
Sponsor	University of California, San Francisco
NCT00656903	Click to show the Detail
Indication	Macular Degeneration
Phase	.
Title	High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration
Status	Completed
Sponsor	National Eye Institute (NEI)
NCT00657202	Click to show the Detail
Indication	Neurofibromatosis Type 1; Cutaneous Neurofibromas
Phase	Phase I
Title	Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
Status	Completed
Sponsor	Massachusetts General Hospital
NCT00661583	Click to show the Detail
Indication	Glaucoma
Phase	Phase I; Phase II
Title	Use of Ranibizumab With Mitomycin C During Trabeculectomy
Status	Completed
Sponsor	University of Colorado, Denver
NCT00667472	Click to show the Detail
Indication	Port-Wine Stain
Phase	Phase I
Title	Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
Status	Withdrawn
Sponsor	University of California, Irvine
NCT00668785	Click to show the Detail
Indication	Proliferative Diabetic Retinopathy; Macular Edema
Phase	Phase II
Title	Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)
Status	Terminated
Sponsor	Jumper, J. Michael, M.D.
NCT00674323	Click to show the Detail
Indication	Polypoidal Choroidal Vasculopathy
Phase	Phase IV
Title	Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
Status	Completed
Sponsor	Novartis
NCT00676559	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase I
Title	Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study
Status	Withdrawn
Sponsor	Johns Hopkins University
NCT00679445	Click to show the Detail
Indication	Wet Age-related Macular Degeneration
Phase	Phase II
Title	A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy
Status	Completed
Sponsor	NeoVista
NCT00680225	Click to show the Detail
Indication	Choroidal Melanoma
Phase	Phase III
Title	Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
Status	Completed
Sponsor	New England Retina Associates
NCT00680498	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase IV
Title	Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment
Status	Completed
Sponsor	Illinois Retina Associates
NCT00681889	Click to show the Detail
Indication	Corneal Neovascularization
Phase	Phase I
Title	Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
Status	Completed
Sponsor	Reza Dana, MD
NCT00682539	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase IV
Title	Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema
Status	Completed
Sponsor	Medical University of Vienna
NCT00685503	Click to show the Detail
Indication	Neovascularization
Phase	Phase I
Title	Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth
Status	Completed
Sponsor	National Eye Institute (NEI)
NCT00685854	Click to show the Detail
Indication	Macular Telangiectasia
Phase	Phase I
Title	Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth
Status	Completed
Sponsor	National Eye Institute (NEI)
NCT00687804	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase III
Title	A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study
Status	Completed
Sponsor	Novartis
NCT00709657	Click to show the Detail
Indication	Macular Degeneration; Regional Blood Flow; Vascular Endothelial Growth Factor
Phase	Not Applicable
Title	The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion
Status	Terminated
Sponsor	Medical University of Vienna
NCT00710229	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase III
Title	Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration
Status	Unknown
Sponsor	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
NCT00713518	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase II
Title	Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).
Status	Completed
Sponsor	Quark Pharmaceuticals
NCT00726466	Click to show the Detail
Indication	Age Related Macular Degeneration; AMD; CNV
Phase	Phase I
Title	Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration
Status	Withdrawn
Sponsor	Vitreous -Retina- Macula Consultants of New York
NCT00726973	Click to show the Detail
Indication	Macular Edema
Phase	Not Applicable
Title	Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)
Status	Withdrawn
Sponsor	Lahey Clinic
NCT00727038	Click to show the Detail
Indication	Glaucoma; New Onset Glaucoma; Neovascular Glaucoma; New Onset Neovascular Glaucoma
Phase	Phase I; Phase II
Title	Lucentis for New Onset Neovascular Glaucoma
Status	Withdrawn
Sponsor	University of Illinois at Chicago
NCT00727753	Click to show the Detail
Indication	Macular Degeneration
Phase	.
Title	VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)
Status	Completed
Sponsor	University of Zurich
NCT00749021	Click to show the Detail
Indication	Retinal Pigment Epithelial Detachment
Phase	Phase I
Title	Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
Status	Completed
Sponsor	Clement K. Chan
NCT00750399	Click to show the Detail
Indication	Radiation Retinopathy; Choroidal Melanoma
Phase	Phase I
Title	Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma
Status	Completed
Sponsor	The New York Eye Cancer Center
NCT00764738	Click to show the Detail
Indication	Neovascular Age Related Macular Degeneration
Phase	Phase II; Phase III
Title	Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration
Status	Completed
Sponsor	Retina Macula Institute
NCT00765921	Click to show the Detail
Indication	Choroidal Melanoma
Phase	Phase I
Title	Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
Status	Completed
Sponsor	Massachusetts Eye and Ear Infirmary
NCT00766337	Click to show the Detail
Indication	Age-related Macular Degeneration; Choroidal Neovascularization
Phase	Phase II
Title	Phase II Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis in Patients With Age-Related Macular Degeneration
Status	Terminated
Sponsor	Santen Inc
NCT00768963	Click to show the Detail
Indication	Pterygium
Phase	Phase I
Title	Ranibizumab for the Inhibition of Neovascularization in Pterygia
Status	Completed
Sponsor	University of Miami
NCT00769145	Click to show the Detail
Indication	Corneal Neovascularization
Phase	Phase I
Title	Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
Status	Completed
Sponsor	University of Miami
NCT00791427	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	.
Title	ERG/EOG Study in AMD Patients Treated With Ranibizumab
Status	Completed
Sponsor	Retina Center, Minnesota
NCT00793923	Click to show the Detail
Indication	Exudative Age-related Macular Degeneration
Phase	Phase I; Phase II
Title	A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD
Status	Completed
Sponsor	Subhransu K. Ray, M.D., Ph.D.
NCT00804934	Click to show the Detail
Indication	Wet AMD
Phase	.
Title	Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis
Status	Completed
Sponsor	Retina Institute of Hawaii
NCT00805233	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase II
Title	Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration
Status	Completed
Sponsor	Oregon Health and Science University
NCT00809419	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase I; Phase II
Title	A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy
Status	Unknown
Sponsor	NeoVista
NCT00811200	Click to show the Detail
Indication	Uveal Melanoma
Phase	Phase II; Phase III
Title	Treatment Of Radiation Retinopathy Trial
Status	Unknown
Sponsor	Leiden University Medical Center
NCT00813891	Click to show the Detail
Indication	Macular Degeneration; Visual Acuity
Phase	Phase IV
Title	Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration
Status	Unknown
Sponsor	McGill University Health Centre/Research Institute of the McGill University Health Centre
NCT00815360	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II
Title	Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion
Status	Completed
Sponsor	Retina Associates of Florida, P.A.
NCT00826371	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase III
Title	Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00826618	Click to show the Detail
Indication	Uveitic Cystoid Macular Edema
Phase	Phase I
Title	Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema
Status	Completed
Sponsor	University of Miami
NCT00831350	Click to show the Detail
Indication	Retinal Vein Occlusion; Posterior Vitreous Detachment
Phase	Phase II
Title	Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations
Status	Completed
Sponsor	Barnes Retina Institute
NCT00837330	Click to show the Detail
Indication	Polypoidal Choroidal Vasculopathy
Phase	Phase I; Phase II
Title	Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
Status	Completed
Sponsor	Southeast Retina Center, Georgia
NCT00841373	Click to show the Detail
Indication	Retinal Ischemia
Phase	Phase I; Phase II
Title	Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease
Status	Completed
Sponsor	Southern New England Retina Associates
NCT00841581	Click to show the Detail
Indication	Pigment Epithelial Detachment
Phase	Phase II
Title	Lucentis to Treat Pigment Epithelial Detachment
Status	Completed
Sponsor	Lawson Health Research Institute
NCT00846625	Click to show the Detail
Indication	Macular Edema; Uveitis
Phase	Phase II
Title	Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids
Status	Withdrawn
Sponsor	University of Utah
NCT00857259	Click to show the Detail
Indication	Choroidal Neo-Vascular Age-onset Macular Degeneration; Age-related Macular Degeneration
Phase	Phase II
Title	The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
Status	Terminated
Sponsor	Novartis Pharmaceuticals
NCT00885794	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II; Phase III
Title	Microperimetry and Optical Coherence Tomography (OCT) With Lucentis for Diabetic Macular Edema (DME)
Status	Unknown
Sponsor	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
NCT00891735	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase III
Title	A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
Status	Completed
Sponsor	Genentech Inc
NCT00892398	Click to show the Detail
Indication	Glaucoma
Phase	Not Applicable
Title	Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab
Status	Completed
Sponsor	Maisonneuve-Rosemont Hospital
NCT00896779	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase II
Title	Lucentis in Advanced Macular Degeneration
Status	Completed
Sponsor	Steven R. Sanislo
NCT00930189	Click to show the Detail
Indication	Subfoveal Choroidal Neovascularization
Phase	Phase II; Phase III
Title	Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization
Status	Unknown
Sponsor	Asociacion para Evitar la Ceguera en Mexico
NCT00931125	Click to show the Detail
Indication	Diabetic Retinopathy
Phase	Phase II
Title	Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone
Status	Unknown
Sponsor	Attila Vajas
NCT00931489	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase II
Title	Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
Status	Completed
Sponsor	Lawrence S. Morse, MD
NCT00942864	Click to show the Detail
Indication	Macular Edema; Retinal Vein Occlusion
Phase	Phase III
Title	Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)
Status	Completed
Sponsor	Novartis Korea Ltd
NCT00955630	Click to show the Detail
Indication	Ocular Histoplasmosis Syndrome
Phase	Phase I; Phase II
Title	Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome
Status	Unknown
Sponsor	Retina Associates of Kentucky
NCT00967213	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase III
Title	Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration
Status	Completed
Sponsor	Novartis Korea Ltd
NCT00976222	Click to show the Detail
Indication	Pigment Epithelial Detachment
Phase	Phase IV
Title	Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments
Status	Completed
Sponsor	University Hospital Muenster
NCT00989989	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase III
Title	Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
Status	Completed
Sponsor	Novartis
NCT00992563	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase II
Title	WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination
Status	Completed
Sponsor	Alcon Research
NCT00993525	Click to show the Detail
Indication	Proliferative Diabetic Retinopathy
Phase	Phase I; Phase II
Title	Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)
Status	Unknown
Sponsor	University of Sao Paulo
NCT00994799	Click to show the Detail
Indication	Macular Edema
Phase	.
Title	Comparison of Intravitreal Ranibizumab and Macular Grid-pattern Laser for Treatment of Diabetic Macular Edema
Status	Unknown
Sponsor	Szeged University
NCT00996437	Click to show the Detail
Indication	Vitreous Hemorrhage; Proliferative Diabetic Retinopathy
Phase	Phase II; Phase III
Title	Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
Status	Completed
Sponsor	Jaeb Center for Health Research
NCT01003106	Click to show the Detail
Indication	Retinal Vein Occlusion
Phase	Phase I; Phase II
Title	Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions
Status	Completed
Sponsor	Peter A Campochiaro, MD
NCT01006538	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase IV
Title	Macular EpiRetinal Brachytherapy Versus Lucentis Only Treatment (MERLOT)
Status	Completed
Sponsor	King's College Hospital NHS Trust
NCT01011374	Click to show the Detail
Indication	Venous Retinal Branch Occlusion; Central Retinal Vein Occlusion; Retinal Vein Occlusion; Depression
Phase	Phase I
Title	Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion
Status	Unknown
Sponsor	Retina Associates of Cleveland, Inc
NCT01014468	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase III
Title	Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration
Status	Unknown
Sponsor	Instituto de Olhos de Goiania
NCT01015495	Click to show the Detail
Indication	Angioid Streaks
Phase	Phase I; Phase II
Title	Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks
Status	Withdrawn
Sponsor	University of Illinois at Chicago
NCT01016873	Click to show the Detail
Indication	Age-related Macular Degeneration; Wet Age-related Macular Degeneration; Eye Diseases; Retinal Diseases
Phase	Phase II
Title	INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
Status	Completed
Sponsor	Oraya Therapeutics
NCT01025063	Click to show the Detail
Indication	Choroidal Neovascularization
Phase	.
Title	Use of Spectral OCT in Combination Therapy
Status	Completed
Sponsor	Barnes Retina Institute
NCT01025232	Click to show the Detail
Indication	Age Related Macular Degeneration; Choroidal Neovascular Membrane; Subfoveal Neovascular Age-related Macular Degeneration; Macular Degeneration; Wet Age-related Macular Degeneration
Phase	Phase I; Phase II
Title	A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
Status	Terminated
Sponsor	David M. Brown, M.D.
NCT01027481	Click to show the Detail
Indication	Retinal Vein Occlusion
Phase	Phase IV
Title	Ranibizumab in Patients With Branch Retinal Vein Occlusion
Status	Completed
Sponsor	Medical University of Vienna
NCT01028248	Click to show the Detail
Indication	Central Retinal Vein Occlusion
Phase	Phase I
Title	Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion
Status	Completed
Sponsor	California Retina Consultants
NCT01030770	Click to show the Detail
Indication	Diabetes Complications
Phase	Phase II; Phase III
Title	Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage:
Status	Completed
Sponsor	King's College Hospital NHS Trust
NCT01037348	Click to show the Detail
Indication	Choroidal Neovascularisation
Phase	Phase II
Title	Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen
Status	Completed
Sponsor	Novartis
NCT01069341	Click to show the Detail
Indication	Rubeosis Iridis; Proliferative Diabetic Retinopathy
Phase	Phase I
Title	Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery
Status	Completed
Sponsor	Bhagat, Neelakshi, M.D., M.P.H.
NCT01077401	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II
Title	Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study
Status	Completed
Sponsor	Johns Hopkins University
NCT01089517	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase II
Title	A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
Status	Completed
Sponsor	Ophthotech Corporation
NCT01102946	Click to show the Detail
Indication	Diabetic Retinopathy; Retinal Neovascularization
Phase	Phase II
Title	Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy
Status	Completed
Sponsor	University of Sao Paulo
NCT01112085	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II
Title	MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2)
Status	Completed
Sponsor	Especialistas en Retina Medica y Quirurgica Grupo de Investigacion
NCT01115556	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase I; Phase II
Title	A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)
Status	Completed
Sponsor	Vitreous -Retina- Macula Consultants of New York
NCT01123564	Click to show the Detail
Indication	Retinal Vein Occlusion; Macular Edema
Phase	Phase II
Title	Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion
Status	Unknown
Sponsor	University of Pecs
NCT01127360	Click to show the Detail
Indication	Exudative Age-related Macular Degeneration
Phase	Phase IV
Title	LUCAS (Lucentis Compared to Avastin Study)
Status	Completed
Sponsor	Oslo University Hospital
NCT01131585	Click to show the Detail
Indication	Visual Impairment Due to Diabetic Macular Edema
Phase	Phase III
Title	Safety and Efficacy of Ranibizumab in Diabetic Macular Edema
Status	Terminated
Sponsor	Novartis Pharmaceuticals
NCT01135914	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase III
Title	Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01148511	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase IV
Title	Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01157065	Click to show the Detail
Indication	Exudative Age-related Macular Degeneration
Phase	Phase II
Title	Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
Status	Completed
Sponsor	Alcon Research
NCT01162746	Click to show the Detail
Indication	Age-related Macular Degeneration; Neovascularization, Choroidal
Phase	Phase II
Title	Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status	Completed
Sponsor	Medical University of Vienna
NCT01169909	Click to show the Detail
Indication	Pterygium
Phase	Phase I
Title	Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia
Status	Completed
Sponsor	University of New Mexico
NCT01170767	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase III
Title	French Evaluation Group Avastin Versus Lucentis
Status	Completed
Sponsor	Hospices Civils de Lyon
NCT01171976	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase III
Title	Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01175395	Click to show the Detail
Indication	Age-related Macular Degeneration; Choroidal Neovascularization
Phase	Phase I; Phase II
Title	20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
Status	Completed
Sponsor	University of Illinois at Chicago
NCT01189019	Click to show the Detail
Indication	Wet Macular Degeneration; Macular Degeneration; Retinal Pigment Epithelial Detachment
Phase	Phase II
Title	HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration
Status	Terminated
Sponsor	Anne Fung MD
NCT01189526	Click to show the Detail
Indication	Branch Retinal Vein Occlusion
Phase	Phase III
Title	Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)
Status	Unknown
Sponsor	Seoul Retina Investigator Group
NCT01196325	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	.
Title	Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy
Status	Unknown
Sponsor	University of Toronto
NCT01198327	Click to show the Detail
Indication	Retinal Vein Occlusion
Phase	Phase III
Title	Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion
Status	Completed
Sponsor	Peter A Campochiaro, MD
NCT01201161	Click to show the Detail
Indication	Diabetic Retinopathy; Retinal Detachment
Phase	Phase II
Title	Ranibizumab for Diabetic Traction Retinal Detachment
Status	Completed
Sponsor	University of Sao Paulo
NCT01205035	Click to show the Detail
Indication	Retinal Diseases; Telangiectasis
Phase	Phase II
Title	High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
Status	Completed
Sponsor	Eye Center of Northern Colorado, P.C.
NCT01213667	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase IV
Title	Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD
Status	Unknown
Sponsor	University of Cologne
NCT01217762	Click to show the Detail
Indication	Age-related Macular Degeneration; Wet Age-related Macular Degeneration; Macular Degeneration; Eye Diseases; Retinal Diseases
Phase	Phase I
Title	Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Status	Unknown
Sponsor	Oraya Therapeutics
NCT01217944	Click to show the Detail
Indication	Pathological Myopia
Phase	Phase III
Title	Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01223612	Click to show the Detail
Indication	Diabetic Retinopathy
Phase	Phase IV
Title	Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation
Status	Completed
Sponsor	Moorfields Eye Hospital NHS Foundation Trust
NCT01225146	Click to show the Detail
Indication	Ischemia; Retinal Vein Occlusion; Pathologic Processes; Retinal Diseases; Eye Diseases
Phase	Phase I
Title	Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
Status	Terminated
Sponsor	David M. Brown, M.D.
NCT01233128	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	.
Title	Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy
Status	Completed
Sponsor	Kyungpook National University Hospital
NCT01238393	Click to show the Detail
Indication	Epiretinal Membrane
Phase	Not Applicable
Title	Treatment of Epiretinal Membranes With Ranibizumab
Status	Completed
Sponsor	Queen's University
NCT01243086	Click to show the Detail
Indication	Wet Macular Degeneration
Phase	Phase II
Title	OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
Status	Completed
Sponsor	McMaster University
NCT01246089	Click to show the Detail
Indication	Myopic Choroidal Neovascularization
Phase	Phase IV
Title	Ranibizumab for Myopic Neovascularization
Status	Unknown
Sponsor	Instituto de Olhos de Goiania
NCT01247220	Click to show the Detail
Indication	Macular Edema; Branch Retinal Vein Occlusion
Phase	Phase II
Title	REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Status	Completed
Sponsor	Retina Associates of Florida, P.A.
NCT01248117	Click to show the Detail
Indication	Polypoidal Choroidal Vasculopathy
Phase	Phase I; Phase II
Title	Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
Status	Unknown
Sponsor	Retina Consultants of Hawaii
NCT01249937	Click to show the Detail
Indication	Wet Macular Degeneration
Phase	Phase II
Title	Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab
Status	Unknown
Sponsor	University Health Network, Toronto
NCT01251978	Click to show the Detail
Indication	Choroidal Melanoma
Phase	Phase II
Title	Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Status	Completed
Sponsor	New England Retina Associates
NCT01253694	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II
Title	Ranibizumab as a Rescue Therapy for Diabetic Macular Edema
Status	Withdrawn
Sponsor	New England Retina Associates
NCT01255774	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase III
Title	Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy
Status	Unknown
Sponsor	The New York Eye & Ear Infirmary
NCT01256632	Click to show the Detail
Indication	Choroidal Neovascularization
Phase	Not Applicable
Title	Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
Status	Completed
Sponsor	Vision Research Foundation
NCT01256827	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	.
Title	Seven Year Update of Macular Degeneration Patients
Status	Completed
Sponsor	University of California, San Francisco
NCT01257815	Click to show the Detail
Indication	Diabetic Retinopathy; Macular Oedema
Phase	Phase IV
Title	Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01269151	Click to show the Detail
Indication	Age-related Macular Degeneration; Retinal Function
Phase	Not Applicable
Title	Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD
Status	Completed
Sponsor	University of Luebeck
NCT01271426	Click to show the Detail
Indication	Polypoidal Choroidal Vasculopathy
Phase	.
Title	Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs
Status	Completed
Sponsor	Nihon University
NCT01277302	Click to show the Detail
Indication	Macular Edema
Phase	Phase IV
Title	A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion
Status	Completed
Sponsor	Genentech Inc
NCT01280929	Click to show the Detail
Indication	High Risk Proliferative Diabetic Retinopathy
Phase	Phase II
Title	Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis Monotherapy Compared With Lucentis Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy
Status	Completed
Sponsor	Jose Cunha-Vaz
NCT01291121	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Not Applicable
Title	Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion
Status	Completed
Sponsor	Yonsei University
NCT01292798	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase I; Phase II
Title	Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab
Status	Completed
Sponsor	California Retina Consultants
NCT01297569	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase IV
Title	Ranibizumab "Treat and Extend" in Diabetic Macular Edma
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01303276	Click to show the Detail
Indication	Central Retinal Vein Occlusion
Phase	.
Title	Retinal Blood Flow in Response to an Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion (CRVO)
Status	Unknown
Sponsor	University of Toronto
NCT01304693	Click to show the Detail
Indication	Exudative Age-related Macular Degeneration
Phase	Phase I; Phase II
Title	ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients
Status	Completed
Sponsor	Alcon Research
NCT01306981	Click to show the Detail
Indication	Diabetic Retinopathy; Retinal Neovascularisation
Phase	Phase IV
Title	Ranibizumab in Diabetic Vitrectomy. A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study
Status	Completed
Sponsor	Moorfields Eye Hospital NHS Foundation Trust
NCT01315275	Click to show the Detail
Indication	Visual Impairment; Macular Edema
Phase	Phase IV
Title	A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01318941	Click to show the Detail
Indication	Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion; Wet Age Related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion
Phase	.
Title	Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01319188	Click to show the Detail
Indication	Age-related Macular Degeneration; Coronary Artery Disease; Cerebrovascular Disorders
Phase	Phase IV
Title	Ranibizumab and the Risk of Arterial Thromboembolic Events
Status	Terminated
Sponsor	Ural State Medical University
NCT01325181	Click to show the Detail
Indication	Chronic Central Serous Chorioretinopathy
Phase	Phase I; Phase II
Title	Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
Status	Completed
Sponsor	Jang Won Heo
NCT01330797	Click to show the Detail
Indication	Age-related Macular Degeneration; Cataract
Phase	.
Title	The Effect of Ranibizumab on Eye Lens Opacity in Cases With Age-Related Macular Degeneration
Status	Completed
Sponsor	Uludag University
NCT01334879	Click to show the Detail
Indication	Radiation Retinopathy
Phase	Phase I
Title	High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy
Status	Completed
Sponsor	The New York Eye Cancer Center
NCT01339949	Click to show the Detail
Indication	Wet Age-related Macular Degeneration; Age-related Macular Degeneration
Phase	Not Applicable
Title	Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
Status	Withdrawn
Sponsor	Oraya Therapeutics
NCT01360151	Click to show the Detail
Indication	Polypoidal Choroidal Vasculopathy
Phase	Not Applicable
Title	Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy
Status	Unknown
Sponsor	Seoul St. Mary's Hospital
NCT01360385	Click to show the Detail
Indication	Central Retinal Vein Occlusion
Phase	.
Title	Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab
Status	Completed
Sponsor	Glostrup University Hospital, Copenhagen
NCT01363570	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Not Applicable
Title	Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes
Status	Completed
Sponsor	McMaster University
NCT01370135	Click to show the Detail
Indication	Neovascular Glaucoma; Rubeosis
Phase	Not Applicable
Title	Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma
Status	Completed
Sponsor	University of Luebeck
NCT01377597	Click to show the Detail
Indication	Retinal Vein Occlusion
Phase	Phase III
Title	Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01396057	Click to show the Detail
Indication	Visual Impairment; Macular Edema; Branch Retinal Vein Occlusion
Phase	Phase III
Title	Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01396083	Click to show the Detail
Indication	Visual Impairment; Macular Edema; Central Retinal Vein Occlusion
Phase	Phase III
Title	Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01397409	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase II
Title	Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
Status	Completed
Sponsor	Allergan
NCT01402544	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase II; Phase III
Title	Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab
Status	Terminated
Sponsor	University of California, San Diego
NCT01406639	Click to show the Detail
Indication	Hereditary Hemorrhagic Telangiectasia (HHT); Nosebleeds
Phase	Phase I
Title	Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Status	Withdrawn
Sponsor	University of California, San Diego
NCT01414153	Click to show the Detail
Indication	Exudative Age-related Macular Degeneration
Phase	Phase II
Title	Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
Status	Completed
Sponsor	Lpath Inc
NCT01428388	Click to show the Detail
Indication	Retinal Vein Occlusion; Macular Edema
Phase	Not Applicable
Title	Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
Status	Completed
Sponsor	Barnes Retina Institute
NCT01442064	Click to show the Detail
Indication	Macular Edema; Retinal Vein Occlusion
Phase	Not Applicable
Title	An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
Status	Completed
Sponsor	Genentech Inc
NCT01445899	Click to show the Detail
Indication	Choroidal Neovascularization; Diabetic Retinopathy; Diabetic Macular Edema
Phase	Phase II
Title	PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Status	Completed
Sponsor	Quark Pharmaceuticals
NCT01447043	Click to show the Detail
Indication	Ophthalmology, Macular Degeneration
Phase	.
Title	Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)
Status	Completed
Sponsor	Bayer
NCT01448018	Click to show the Detail
Indication	Central Retinal Vein Occlusion
Phase	Phase IV
Title	Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion
Status	Completed
Sponsor	Centre Hospitalier Intercommunal Creteil
NCT01453920	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase IV
Title	Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing
Status	Completed
Sponsor	University Health Network, Toronto
NCT01464723	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase IV
Title	Study EvAluating Genotypes While Using Lucentis 2
Status	Completed
Sponsor	University of California, San Diego
NCT01469156	Click to show the Detail
Indication	Polypoidal Choroidal Vasculopathy
Phase	Phase I; Phase II
Title	Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
Status	Unknown
Sponsor	Southeast Retina Center, Georgia
NCT01471691	Click to show the Detail
Indication	Branch Retinal Vein Occlusion; Central Retinal Vein Occlusion; Macular Edema
Phase	Phase I; Phase II
Title	Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
Status	Completed
Sponsor	Hanscom, Thomas, M.D.
NCT01472510	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II
Title	Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy
Status	Completed
Sponsor	Vitreo-Retinal Associates, PC
NCT01473251	Click to show the Detail
Indication	Exudative Macular Degeneration; Diabetic Macular Edema
Phase	Not Applicable
Title	Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration
Status	Completed
Sponsor	Vitreo-Retinal Associates, Michigan
NCT01476449	Click to show the Detail
Indication	Diabetic Retinopathy; Macular Edema
Phase	Phase II
Title	Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
Status	Completed
Sponsor	Retina Vitreous Associates of Florida
NCT01487629	Click to show the Detail
Indication	Diabetic Retinopathy; Macular Edema
Phase	Phase II
Title	Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema
Status	Unknown
Sponsor	University of Sao Paulo
NCT01489189	Click to show the Detail
Indication	Proliferative Diabetic Retinopathy
Phase	Phase III
Title	Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status	Completed
Sponsor	Jaeb Center for Health Research
NCT01492400	Click to show the Detail
Indication	Macular Edema
Phase	Phase II
Title	Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema
Status	Completed
Sponsor	Allergan
NCT01494805	Click to show the Detail
Indication	Macular Degeneration; Age-related Maculopathies; Retinal Degeneration; Retinal Neovascularization; Eye Diseases
Phase	Phase I; Phase II
Title	Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration
Status	Completed
Sponsor	Lions Eye Institute, Perth, Western Australia
NCT01500915	Click to show the Detail
Indication	Exudative Age-related Macular Degeneration
Phase	Phase IV
Title	FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration
Status	Completed
Sponsor	Institut de la Macula y la Retina
NCT01516294	Click to show the Detail
Indication	Polypoidal Chorodial Vasculopathy; Age Related Macular Degeneration
Phase	Not Applicable
Title	IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD
Status	Unknown
Sponsor	Oraya Therapeutics
NCT01521819	Click to show the Detail
Indication	Retinal Pigment Epithelial Detachment With Vascularization; Age Related Macular Degeneration
Phase	Not Applicable
Title	Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration
Status	Unknown
Sponsor	Oraya Therapeutics Inc
NCT01535261	Click to show the Detail
Indication	Macular Edema; Central Retinal Vein Occlusion
Phase	Phase III
Title	Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01542866	Click to show the Detail
Indication	Age Related Macular Degeneration (AMD)
Phase	Not Applicable
Title	A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01552408	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase I; Phase II
Title	Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)
Status	Completed
Sponsor	David M. Brown, M.D.
NCT01564108	Click to show the Detail
Indication	Uveitis Related Cystoid Macular Edema; Steroid-induced Glaucoma - Borderline
Phase	Phase II
Title	The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema
Status	Completed
Sponsor	Moorfields Eye Hospital NHS Foundation Trust
NCT01565148	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II
Title	A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)
Status	Terminated
Sponsor	Johns Hopkins University
NCT01570608	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase III
Title	Lucentis KAV Study
Status	Completed
Sponsor	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
NCT01581151	Click to show the Detail
Indication	Retinal Vein Occlusion
Phase	Not Applicable
Title	Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion
Status	Unknown
Sponsor	Brian Burke, MPH
NCT01594281	Click to show the Detail
Indication	Proliferative Diabetic Retinopathy (PDR)
Phase	Phase II
Title	Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01599650	Click to show the Detail
Indication	Branch Retinal Vein Occlusion
Phase	Phase III
Title	Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01610557	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II
Title	Ranibizumab and Bevacizumab for Diabetic Macular Edema
Status	Completed
Sponsor	National Eye Institute (NEI)
NCT01626339	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Not Applicable
Title	Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter
Status	Unknown
Sponsor	University of Malaya
NCT01627249	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase III
Title	Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
Status	Completed
Sponsor	Jaeb Center for Health Research
NCT01628354	Click to show the Detail
Indication	Choroidal Neovascularization; Retinal Pigment Epithelial Detachment
Phase	Phase IV
Title	Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration
Status	Completed
Sponsor	University of Melbourne
NCT01635790	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II; Phase III
Title	Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME)
Status	Unknown
Sponsor	Prof. dr. R.O. Schlingemann
NCT01635803	Click to show the Detail
Indication	Retinal Vein Occlusion
Phase	Phase II; Phase III
Title	Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)
Status	Unknown
Sponsor	Academisch Medisch Centrum-Universiteit van Amsterdam (AMC-UvA)
NCT01638858	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Not Applicable
Title	Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)
Status	Completed
Sponsor	University of Luebeck
NCT01644513	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	.
Title	Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients
Status	Completed
Sponsor	Sequenom
NCT01661946	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase III
Title	Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye
Status	Completed
Sponsor	Queen's University
NCT01666236	Click to show the Detail
Indication	Choroidal Neovascularization; Retinal Pigment Epithelial Detachment
Phase	Phase IV
Title	Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy
Status	Withdrawn
Sponsor	Federal University of Sao Paulo
NCT01669447	Click to show the Detail
Indication	Degeneration of Macula and Posterior Pole
Phase	Phase IV
Title	Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis
Status	Unknown
Sponsor	Osias Francisco de Souza
NCT01674569	Click to show the Detail
Indication	Exudative Macular Degeneration
Phase	Phase I; Phase II
Title	Pilot Study of X-82 in Patients With Wet AMD
Status	Completed
Sponsor	Tyrogenex
NCT01676506	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Not Applicable
Title	Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)
Status	Unknown
Sponsor	Russian Academy of Medical Sciences
NCT01710839	Click to show the Detail
Indication	Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Phase	Phase IV
Title	Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
Status	Completed
Sponsor	Charles C Wykoff, PhD, MD
NCT01746563	Click to show the Detail
Indication	Diabetic Retinopathy; Retinal Diseases; Eye Diseases; Diabetic Angiopathies; Vascular Diseases; Cardiovascular Diseases
Phase	Phase I; Phase II
Title	Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy
Status	Completed
Sponsor	University of Sao Paulo
NCT01748292	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase III
Title	Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab
Status	Completed
Sponsor	Charles C Wykoff, PhD, MD
NCT01760746	Click to show the Detail
Indication	Proliferative Diabetic Retinopathy (PDR)
Phase	.
Title	Comparison of Changes of Inflammatory Proteins in Aqueous Humour of Subjects Treated With Avastin vs Lucentis
Status	Completed
Sponsor	University of British Columbia
NCT01771081	Click to show the Detail
Indication	Ophthalmology; Macular Edema; Macular Degeneration
Phase	.
Title	Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy
Status	Completed
Sponsor	Bayer
NCT01775124	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase IV
Title	Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01780935	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase III
Title	Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01795209	Click to show the Detail
Indication	Branch Retinal Vein Occlusion; Macular Edema
Phase	Phase IV
Title	Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision
Status	Terminated
Sponsor	Seoul National University Bundang Hospital
NCT01810042	Click to show the Detail
Indication	Exudative Age-related Macular Degeneration
Phase	Phase IV
Title	Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Status	Completed
Sponsor	Pusan National University Hospital
NCT01823965	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II
Title	Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment
Status	Completed
Sponsor	Poitiers University Hospital
NCT01824043	Click to show the Detail
Indication	Diabetic Retinopathy; Vitreous Hemorrhage
Phase	Phase IV
Title	Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage
Status	Unknown
Sponsor	Hospital Regional de Sao Jose-Dr. Homero de Miranda Gomes
NCT01827722	Click to show the Detail
Indication	Macular Edema; Central Retinal Vein Occlusion
Phase	Phase IV
Title	Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
Status	Unknown
Sponsor	Valley Retina Institute
NCT01831947	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase IV
Title	Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.
Status	Completed
Sponsor	Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
NCT01833325	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Not Applicable
Title	Proton Radiation Therapy for Macular Degeneration
Status	Completed
Sponsor	University of Florida
NCT01835067	Click to show the Detail
Indication	Exudative Macular Degeneration; Retinal Hemorrhage
Phase	Phase II; Phase III
Title	Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD
Status	Completed
Sponsor	King's College Hospital NHS Trust
NCT01840410	Click to show the Detail
Indication	Choroidal Neovascularization (CNV)
Phase	Phase III
Title	Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01845844	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase I; Phase II
Title	Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab
Status	Unknown
Sponsor	Southeast Retina Center, Georgia
NCT01846273	Click to show the Detail
Indication	Age-related Macular Degeneration; Polypoidal Choroidal Vasculopathy
Phase	Phase IV
Title	Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01846299	Click to show the Detail
Indication	Macular Edema (ME)
Phase	Phase III
Title	To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01849692	Click to show the Detail
Indication	Exudative Age-related Macular Degeneration
Phase	Phase II
Title	ESBA1008 Microvolume Study
Status	Completed
Sponsor	Alcon Research
NCT01863199	Click to show the Detail
Indication	Neovascular Age Related Macular Degeneration
Phase	Phase IV
Title	Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
Status	Completed
Sponsor	Retinal Consultants of Arizona
NCT01875770	Click to show the Detail
Indication	Retinal Vein Occlusion
Phase	.
Title	Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
Status	Terminated
Sponsor	Johns Hopkins University
NCT01884597	Click to show the Detail
Indication	PCV; Polypoidal Choroidal Vasculopathy
Phase	Phase I; Phase II
Title	Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)
Status	Completed
Sponsor	Hawaii Pacific Health
NCT01899066	Click to show the Detail
Indication	Retinoblastoma
Phase	Phase II
Title	Efficacy Study of Lucentis in the Treatment of Retinoblastoma
Status	Unknown
Sponsor	Sun Yat-sen University
NCT01908816	Click to show the Detail
Indication	Choroidal Neovascularization; Macular Edema; Glaucoma, Neovascular; Diabetic Retinopathy
Phase	Phase III
Title	An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01914159	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase II
Title	Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study
Status	Completed
Sponsor	University Hospital, Bonn
NCT01922102	Click to show the Detail
Indication	Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
Phase	Phase III
Title	Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01922154	Click to show the Detail
Indication	Glaucoma, Neovascular
Phase	Phase IV
Title	Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma
Status	Completed
Sponsor	Siriraj Hospital
NCT01926977	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase I; Phase II
Title	Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
Status	Completed
Sponsor	Arshad Khanani
NCT01933152	Click to show the Detail
Indication	Macular Degeneration
Phase	.
Title	Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration
Status	Completed
Sponsor	Bayer
NCT01934556	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase I; Phase II
Title	A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema
Status	Completed
Sponsor	Palmetto Retina Center, LLC
NCT01940900	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase III
Title	A Phase III Safety and Efficacy Study of Fovista (E10030) Intravitreous Administration in Combination With Lucentis Compared to Lucentis Monotherapy
Status	Terminated
Sponsor	Ophthotech Corporation
NCT01941329	Click to show the Detail
Indication	High Risk Proliferative Diabetic Retinopathy
Phase	Phase II; Phase III
Title	Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.
Status	Completed
Sponsor	Association for Innovation and Biomedical Research on Light and Image
NCT01942213	Click to show the Detail
Indication	Neovascular Age Related Macular Degeneration
Phase	.
Title	Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.
Status	Completed
Sponsor	Prism Vision Group
NCT01944839	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase III
Title	A Phase III Safety and Efficacy Study of Fovista (E10030) Intravitreous Administration in Combination With Lucentis Compared to Lucentis Monotherapy
Status	Terminated
Sponsor	Ophthotech Corporation
NCT01945866	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II
Title	Phase II Combination Steroid and Anti-VEGF for Persistent DME
Status	Completed
Sponsor	Jaeb Center for Health Research
NCT01947881	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	.
Title	Characterization of Eyes With Diabetic Macular Edema That Show Different Treatment Response to Intravitreal Anti-VEGF (CHARTRES)
Status	Completed
Sponsor	Association for Innovation and Biomedical Research on Light and Image
NCT01948830	Click to show the Detail
Indication	Age-related Macular Degeneration; Choroidal Neovascularization
Phase	Phase III
Title	Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01958918	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase IV
Title	Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01968239	Click to show the Detail
Indication	Branch Retinal Vein Occlusion
Phase	Phase II
Title	Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT
Status	Completed
Sponsor	University of Leipzig
NCT01968486	Click to show the Detail
Indication	Myopia, Degenerative
Phase	Phase I
Title	Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia
Status	Completed
Sponsor	University of Campania "Luigi Vanvitelli"
NCT01968616	Click to show the Detail
Indication	Macular Edema Due to BRVO/CRVO
Phase	Not Applicable
Title	Ranibizumab Treatment for Retinal Vein Occlusion
Status	Unknown
Sponsor	Kyoto University, Graduate School of Medicine
NCT01972763	Click to show the Detail
Indication	Recalcitrant Wet Age-related Macular Degeneration
Phase	Phase I; Phase II
Title	Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.
Status	Completed
Sponsor	Northern California Retina Vitreous Associates
NCT01972789	Click to show the Detail
Indication	Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD
Phase	Phase IV
Title	Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200m at the Foveal Centre)
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01976312	Click to show the Detail
Indication	Central Retinal Vein Occlusion
Phase	Phase III
Title	Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01976338	Click to show the Detail
Indication	Macular Edema Secondary to Branch Retinal Vein Occlusion
Phase	Phase III
Title	Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01982435	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase I; Phase II
Title	Safety and Efficacy of Ranibizumab for Diabetic Macular Edema
Status	Completed
Sponsor	Justis Ehlers
NCT01986907	Click to show the Detail
Indication	Wet Age Related Macular Degeneration
Phase	Phase IV
Title	Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01988662	Click to show the Detail
Indication	Neovacular Age-related Macular Degeneration
Phase	Phase IV
Title	UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01994174	Click to show the Detail
Indication	Macular Disease
Phase	.
Title	Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics
Status	Recruiting
Sponsor	University of Nebraska
NCT01994291	Click to show the Detail
Indication	Macular Edema, Diabetic
Phase	Phase II
Title	A Phase II, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
Status	Terminated
Sponsor	Pfizer
NCT02005432	Click to show the Detail
Indication	Proliferative Diabetic Retinopathy
Phase	Phase IV
Title	PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy
Status	Unknown
Sponsor	University of Sao Paulo
NCT02022540	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase I
Title	Phase I Study of Topical Ocular PAN-90806 for Neovascular AMD
Status	Completed
Sponsor	PanOptica Inc
NCT02032173	Click to show the Detail
Indication	Macular Edema; Macular Degeneration; Diabetes
Phase	Phase III
Title	Efficacy and Safety of Lucentis Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase
Status	Terminated
Sponsor	Novartis Pharmaceuticals
NCT02033031	Click to show the Detail
Indication	Branch Retinal Vein Occlusion
Phase	Phase III
Title	Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion
Status	Completed
Sponsor	Medical University of Vienna
NCT02034006	Click to show the Detail
Indication	Choroidal Neovascularization Secondary to Pathologic Myopia
Phase	Phase III
Title	A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT02035722	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase II; Phase III
Title	Intravitreal Injections-related Anxiety
Status	Completed
Sponsor	University Health Network, Toronto
NCT02036723	Click to show the Detail
Indication	Wet Age-related Macular Degeneration
Phase	Phase III
Title	Safety and Efficacy Study of BCD-021 Compared to Lucentis in Patients With Neovascular Wet Age-related Macular Degeneration
Status	Withdrawn
Sponsor	Biocad
NCT02050828	Click to show the Detail
Indication	Diabetic Macular Edema (DME)
Phase	Phase II
Title	The TIME-2 Study: A Phase II Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
Status	Completed
Sponsor	Aerpio Therapeutics
NCT02055911	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase IV
Title	Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema
Status	Withdrawn
Sponsor	Federal University of Sao Paulo
NCT02059772	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase IV
Title	Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema
Status	Unknown
Sponsor	GWT-TUD GmbH
NCT02060604	Click to show the Detail
Indication	Wet Macular Degeneration
Phase	Phase IV
Title	Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
Status	Completed
Sponsor	Universit degli Studi di Brescia
NCT02067013	Click to show the Detail
Indication	Proliferative Diabetic Retinopathy; Macular Degeneration; Macular Hole; Neovascular Glaucoma
Phase	Phase II
Title	Analysis of Aqueous and Vitreous Humor
Status	Unknown
Sponsor	California Retina Consultants
NCT02081339	Click to show the Detail
Indication	Macular Disease
Phase	.
Title	Cohort Study of the Clinical Course of Macular Diseases in Japanese
Status	Recruiting
Sponsor	Kyoto University, Graduate School of Medicine
NCT02089503	Click to show the Detail
Indication	Exudative Age-related Macular Degeneration
Phase	.
Title	Monocentric Retrospective Observational Study on Patients With Macular Degeneration
Status	Unknown
Sponsor	Hospital St. Joseph, Marseille, France
NCT02091505	Click to show the Detail
Indication	Central Retinal Vein Occlusion
Phase	Not Applicable
Title	Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO
Status	Unknown
Sponsor	Mie University
NCT02103738	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	.
Title	Canadian Treat and Extend Analysis Trial With Ranibizumab
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT02107131	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase IV
Title	Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab
Status	Completed
Sponsor	California Retina Consultants
NCT02118831	Click to show the Detail
Indication	Age-related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion
Phase	Phase I; Phase II
Title	Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
Status	Completed
Sponsor	California Retina Consultants
NCT02121353	Click to show the Detail
Indication	Age Related Macular Degeneration (AMD)
Phase	Phase I; Phase II
Title	Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration
Status	Completed
Sponsor	Pfenex, Inc
NCT02127684	Click to show the Detail
Indication	Persistent Diabetic Macular Edema
Phase	Phase II
Title	Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing
Status	Withdrawn
Sponsor	Maturi, Raj K., M.D., P.C.
NCT02130024	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase IV
Title	A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT02131350	Click to show the Detail
Indication	Diabetic Macula Edema
Phase	Phase IV
Title	Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula Edema
Status	Completed
Sponsor	Shinshu University
NCT02134457	Click to show the Detail
Indication	Retinopathy of Prematurity (ROP)
Phase	Phase II
Title	Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity
Status	Completed
Sponsor	University Hospital Freiburg
NCT02140151	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase I; Phase II
Title	Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
Status	Unknown
Sponsor	Southern California Desert Retina Consultants, MC
NCT02140411	Click to show the Detail
Indication	Retinal Vein Occlusion; Age Related Macular Degeneration
Phase	Phase IV
Title	Efficacy and Safety of Lucentis (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT02142114	Click to show the Detail
Indication	Pain
Phase	Phase I
Title	Assessment of Comfort Level Following an Intravitreal Injection by 30 or 32 Gauge Needles
Status	Unknown
Sponsor	Retina Health Center
NCT02144662	Click to show the Detail
Indication	Researcher-Subject Relations
Phase	Not Applicable
Title	Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion
Status	Completed
Sponsor	St. Marianna University School of Medicine
NCT02158624	Click to show the Detail
Indication	Visual Disorder Due to Age-related Macula Degeneration
Phase	Not Applicable
Title	Ranibizumab Treatment for Age-Related Macular Degeneretion
Status	Unknown
Sponsor	Kyushu University
NCT02161575	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase IV
Title	Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT02164604	Click to show the Detail
Indication	Retinopathy of Prematurity
Phase	Not Applicable
Title	Lucentis to Treat Retinopathy of Prematurity (ROP) 3 Plus Disease
Status	Completed
Sponsor	Kantonsspital Aarau
NCT02169648	Click to show the Detail
Indication	Macular Edema; Branch Retinal Vein Occlusion; Central Retinal Vein Occlusion
Phase	Not Applicable
Title	Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion
Status	Unknown
Sponsor	Tokyo Medical University
NCT02173496	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	.
Title	Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
Status	Completed
Sponsor	Aston University
NCT02174211	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Not Applicable
Title	A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.
Status	Completed
Sponsor	King's College Hospital NHS Trust
NCT02175940	Click to show the Detail
Indication	Myopic Choroidal Neovascularization; VEGF Aqueous Level; PEDF Aqueous Level
Phase	.
Title	VEGF and PEDF in Patients With Myopic Choroidal Neovascularization
Status	Completed
Sponsor	Universita degli Studi di Brescia
NCT02194803	Click to show the Detail
Indication	Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV
Phase	.
Title	Observation of Treatment Patterns With Lucentis in Approved Indications
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT02207712	Click to show the Detail
Indication	Diabetic Macular Oedema
Phase	Not Applicable
Title	Noctura400 Treatment for Diabetic Retinopathy (CANDLE)
Status	Active, not recruiting
Sponsor	PolyPhotonix Medical
NCT02218177	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	.
Title	Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD
Status	Completed
Sponsor	University Health Network, Toronto
NCT02222207	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase II
Title	Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
Status	Terminated
Sponsor	Bayer
NCT02222610	Click to show the Detail
Indication	Radiation Retinopathy
Phase	Phase II
Title	Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
Status	Completed
Sponsor	Greater Houston Retina Research
NCT02243878	Click to show the Detail
Indication	Neovascular (Wet) Age-related Macular Degeneration
Phase	Phase III
Title	Stereotactic Radiotherapy for Wet AMD (STAR)
Status	Active, not recruiting
Sponsor	King's College Hospital NHS Trust
NCT02257632	Click to show the Detail
Indication	Wet Age-related Macular Degeneration
Phase	Phase IV
Title	Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT02258009	Click to show the Detail
Indication	Visual Impairment Due to Diabetic Macular Edema
Phase	Phase IV
Title	Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Status	Withdrawn
Sponsor	Novartis Pharmaceuticals
NCT02259088	Click to show the Detail
Indication	Diabetic Macular Edema; Visual Impairment
Phase	Phase III
Title	A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT02274259	Click to show the Detail
Indication	Central Retinal Vein Occlusion
Phase	Phase IV
Title	Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen
Status	Completed
Sponsor	Anders Kvanta
NCT02281292	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase I
Title	A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema
Status	Withdrawn
Sponsor	Alcon Research
NCT02291887	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	.
Title	Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept
Status	Completed
Sponsor	Associated Retinal Consultants, Michigan
NCT02294656	Click to show the Detail
Indication	CYSTOID MACULAR EDEMA
Phase	Phase I
Title	Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide
Status	Completed
Sponsor	Soll Eye
NCT02296567	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase II; Phase III
Title	Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients
Status	Unknown
Sponsor	East Florida Eye Institute
NCT02302079	Click to show the Detail
Indication	Diabetes Mellitus; Diabetic Macular Edema
Phase	Phase II
Title	A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)
Status	Completed
Sponsor	Astellas Pharma Europe B.V.
NCT02302989	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase I; Phase II
Title	Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration
Status	Completed
Sponsor	Leonard Feiner, MD, PhD
NCT02304068	Click to show the Detail
Indication	Acute Macular Degeneration
Phase	Not Applicable
Title	The Accuracy of Home Monitoring for Acute Macular Degeneration (AMD) Disease Activity
Status	Completed
Sponsor	The Leeds Teaching Hospitals NHS Trust
NCT02321267	Click to show the Detail
Indication	Macular Disease
Phase	Phase IV
Title	Cohort Study of the Clinical Course of Macular Diseases in Kagawa
Status	Recruiting
Sponsor	Kagawa University
NCT02321839	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase IV
Title	Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.
Status	Completed
Sponsor	Nagoya City University
NCT02328118	Click to show the Detail
Indication	Proliferative Diabetic Retinopathy
Phase	Phase II; Phase III
Title	25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China
Status	Unknown
Sponsor	JUNYAN ZHANG
NCT02328209	Click to show the Detail
Indication	Exudative Age-related Macular Degeneration
Phase	Not Applicable
Title	Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
Status	Unknown
Sponsor	Mie University
NCT02329132	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	.
Title	Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema
Status	Completed
Sponsor	Kagawa University
NCT02342392	Click to show the Detail
Indication	Pterygium
Phase	Phase II; Phase III
Title	Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study
Status	Completed
Sponsor	Universiti Sains Malaysia
NCT02355028	Click to show the Detail
Indication	Exudative Age-related Macular Degeneration
Phase	Phase II
Title	LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
Status	Completed
Sponsor	Alcon, a Novartis Company
NCT02358889	Click to show the Detail
Indication	Choroidal Neovascularization; Age-related Macular Degeneration
Phase	Phase II
Title	Study Evaluating Intravitreal hI-con1?in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status	Completed
Sponsor	Iconic Therapeutics
NCT02363621	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II
Title	Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME
Status	Completed
Sponsor	Arshad Khanani
NCT02366468	Click to show the Detail
Indication	Diabetic Retinopathy
Phase	Phase IV
Title	Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT02372916	Click to show the Detail
Indication	Age-related Macular Degeneration; Geographic Atrophy
Phase	.
Title	Geographic Atrophy and Intravitreal Ranibizumab Injections
Status	Unknown
Sponsor	University Health Network, Toronto
NCT02375971	Click to show the Detail
Indication	Retinopathy of Prematurity
Phase	Phase III
Title	RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT02387957	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase II
Title	A 24 Month Phase IIa Open Label, Randomized Study of Avastin, Lucentis, or Eylea (Anti-VEGF Therapy) Administered in Combination With Fovista (Anti-PDGF BB Pegylated Aptamer)
Status	Terminated
Sponsor	Ophthotech Corporation
NCT02398500	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase I; Phase II
Title	Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
Status	Terminated
Sponsor	Alcon Research
NCT02420132	Click to show the Detail
Indication	Macular Edema; Macular Degeneration
Phase	.
Title	Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis)
Status	Completed
Sponsor	Hoffmann-La Roche
NCT02447185	Click to show the Detail
Indication	Proliferative Diabetic Retinopathy
Phase	Phase III
Title	25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial
Status	Recruiting
Sponsor	JUNYAN ZHANG
NCT02448446	Click to show the Detail
Indication	Diabetic Macular Edema; Hard Lipid Exudates
Phase	Phase I; Phase II
Title	The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates
Status	Completed
Sponsor	South Coast Retina Center
NCT02462304	Click to show the Detail
Indication	Diabetic Macula Edema
Phase	Phase IV
Title	To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema
Status	Unknown
Sponsor	The University of Hong Kong
NCT02474225	Click to show the Detail
Indication	Intraocular Pressure
Phase	.
Title	Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent
Status	Completed
Sponsor	Prince of Songkla University
NCT02478515	Click to show the Detail
Indication	Branch Retinal Vein Occlusion
Phase	Phase IV
Title	Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion
Status	Completed
Sponsor	Nagoya City University
NCT02484690	Click to show the Detail
Indication	Choroidal Neovascularization
Phase	Phase II
Title	A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Status	Completed
Sponsor	Hoffmann-La Roche
NCT02510794	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase II
Title	Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
Status	Completed
Sponsor	Genentech Inc
NCT02511067	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II
Title	Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study
Status	Withdrawn
Sponsor	University of Nebraska
NCT02511613	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase II
Title	Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
Status	Withdrawn
Sponsor	Ohr Pharmaceutical Inc
NCT02522897	Click to show the Detail
Indication	Central Retinal Vein Occlusion With Macular Edema
Phase	Phase IV
Title	Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas
Status	Unknown
Sponsor	PD. Dr. med. Armin Wolf
NCT02527733	Click to show the Detail
Indication	Branch Retinal Vein Occlusion
Phase	Phase IV
Title	Retinal Sensitivity in BRVO After Anti-VEGF Therapy
Status	Unknown
Sponsor	Fukushima Medical University
NCT02530918	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration; Diabetic Macular Edema
Phase	Phase I
Title	Study of DS-7080a for the Treatment of Macular Degeneration
Status	Completed
Sponsor	Daiichi Sankyo Inc
NCT02543229	Click to show the Detail
Indication	Eye Diseases; Macular Degeneration; Retinal Diseases; Retinal Degeneration; Neovascularization, Pathologic
Phase	.
Title	Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis?in Patients With Wet AMD
Status	Completed
Sponsor	Phase I
NCT02577107	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase IV
Title	Head to Head Study of Anti-VEGF Treatment.
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT02591914	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase I
Title	An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration
Status	Completed
Sponsor	Retinal Consultants of Arizona
NCT02611778	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase III
Title	Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration
Status	Completed
Sponsor	Bioeq GmbH
NCT02614937	Click to show the Detail
Indication	Retinal Vein Occlusion; Macular Edema
Phase	Phase I; Phase II
Title	Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion
Status	Completed
Sponsor	Ohr Pharmaceutical Inc
NCT02623426	Click to show the Detail
Indication	Uveitis; Macular Edema
Phase	Phase III
Title	Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
Status	Recruiting
Sponsor	JHSPH Center for Clinical Trials
NCT02634970	Click to show the Detail
Indication	Wet Age-related Macular Degeneration (Wet AMD)
Phase	Phase IV
Title	CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab
Status	Withdrawn
Sponsor	Novartis Pharmaceuticals
NCT02640664	Click to show the Detail
Indication	Retinopathy of Prematurity
Phase	Phase III
Title	Rainbow Extension Study
Status	Active, not recruiting
Sponsor	Novartis Pharmaceuticals
NCT02641457	Click to show the Detail
Indication	Glaucoma; Rubeosis Iridis
Phase	Phase III
Title	Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis
Status	Completed
Sponsor	Instituto de Olhos de Goiania
NCT02646670	Click to show the Detail
Indication	Retinal Diseases
Phase	Phase IV
Title	Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema
Status	Completed
Sponsor	Instituto de Olhos de Goiania
NCT02647515	Click to show the Detail
Indication	Diabetic Retinopathy; Glaucoma, Neovascular
Phase	Phase IV
Title	Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma
Status	Completed
Sponsor	Ruijin Hospital
NCT02651168	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase IV
Title	Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study
Status	Unknown
Sponsor	Unity Health Toronto
NCT02665689	Click to show the Detail
Indication	Visual Acuity Reduced Transiently; Macular Edema, Cystoid
Phase	Phase IV
Title	Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab
Status	Terminated
Sponsor	Prof. Dr. Antonia M. Joussen
NCT02684084	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase IV
Title	Combination OZURDEX & LUCENTIS vs. OZURDEX Monotherapy in Incomplete-Responders With Diabetic Macular Edema
Status	Terminated
Sponsor	North Toronto Eye Care Laser and Eye Specialists
NCT02698566	Click to show the Detail
Indication	Macular Edema
Phase	Phase III
Title	A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis) Prefilled Syringe (PFS)
Status	Completed
Sponsor	Genentech Inc
NCT02699450	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II
Title	A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema
Status	Completed
Sponsor	Hoffmann-La Roche
NCT02707575	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	.
Title	Cytokeratin 8 Level in Age-related Macular Degeneration
Status	Completed
Sponsor	Gangnam Severance Hospital
NCT02727881	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase III
Title	Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
Status	Unknown
Sponsor	Ohr Pharmaceutical Inc
NCT02769169	Click to show the Detail
Indication	Polypoidal Choroidal Vasculopathy
Phase	Phase II; Phase III
Title	Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy
Status	Terminated
Sponsor	Sun Yat-sen University
NCT02806752	Click to show the Detail
Indication	Wet Macular Degeneration
Phase	Phase IV
Title	Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy
Status	Unknown
Sponsor	Aier School of Ophthalmology, Central South University
NCT02810808	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase IV
Title	Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD
Status	Unknown
Sponsor	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT02834663	Click to show the Detail
Indication	Nonproliferative Diabetic Retinopathy
Phase	Phase IV
Title	Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
Status	Completed
Sponsor	Wonkwang University Hospital
NCT02843490	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase IV
Title	Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration
Status	Completed
Sponsor	Johannes Gutenberg University Mainz
NCT02857491	Click to show the Detail
Indication	Proliferative Diabetic Retinopathy
Phase	Not Applicable
Title	Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy
Status	Completed
Sponsor	Sun Yat-sen University
NCT02859441	Click to show the Detail
Indication	Von Hippel-Lindau Syndrome
Phase	Phase I; Phase II
Title	A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Status	Completed
Sponsor	National Eye Institute (NEI)
NCT02864472	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase IV
Title	Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
Status	Unknown
Sponsor	Seoul National University Hospital
NCT02878681	Click to show the Detail
Indication	Visual Impairment Due to Diabetic Macular Edema
Phase	Phase IV
Title	24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.
Status	Withdrawn
Sponsor	Novartis Pharmaceuticals
NCT02914626	Click to show the Detail
Indication	Glaucoma, Neovascular; Ranibizumab
Phase	Phase III
Title	Intravitreal Ranibizumab (Lucentis) for Neovascular Glaucoma- a Randomized Controlled Study
Status	Unknown
Sponsor	LEANDRO CABRAL ZACHARIAS
NCT02933905	Click to show the Detail
Indication	Diabetic Macular Edema; Vitreomacular Interface; Anti-VEGF Treatment
Phase	.
Title	Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection
Status	Completed
Sponsor	Fundaci Institut Germans Trias i Pujol
NCT02944227	Click to show the Detail
Indication	Wet Macular Degeneration
Phase	Phase IV
Title	Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
Status	Completed
Sponsor	Seoul National University Hospital
NCT02953938	Click to show the Detail
Indication	Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Phase	Phase IV
Title	Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT02976194	Click to show the Detail
Indication	Exudative Age-related Macular Degeneration; Polypoidal Choroidal Vasculopathy
Phase	Phase IV
Title	Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
Status	Active, not recruiting
Sponsor	Pusan National University Hospital
NCT02979665	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	.
Title	Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema
Status	Completed
Sponsor	Lawson Health Research Institute
NCT03038048	Click to show the Detail
Indication	Age Related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion
Phase	Not Applicable
Title	30g vs 33g Needle for Intravitreal Injections
Status	Completed
Sponsor	Wills Eye
NCT03038880	Click to show the Detail
Indication	Neovascularization, Choroidal; Age-related Macular Degeneration
Phase	Phase II
Title	Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration
Status	Completed
Sponsor	Hoffmann-La Roche
NCT03042871	Click to show the Detail
Indication	Choroidal Neovascularization
Phase	Phase IV
Title	Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization
Status	Completed
Sponsor	Zhongshan Ophthalmic Center, Sun Yat-sen University
NCT03054766	Click to show the Detail
Indication	Branch Retinal Vein Occlusion; Ranibizumab; Laser Photocoagulation
Phase	Not Applicable
Title	Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO
Status	Terminated
Sponsor	Beijing Hospital
NCT03056092	Click to show the Detail
Indication	Age Related Macular Degeneration; Diabetic Macular Edema; Macular Edema; Retinal Vein Occlusion
Phase	Phase IV
Title	Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab
Status	Recruiting
Sponsor	Unity Health Toronto
NCT03071055	Click to show the Detail
Indication	Exudative Age Related Macular Degeneration
Phase	Phase II
Title	Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF
Status	Completed
Sponsor	Southeast Clinical Research Associates, LLC
NCT03097068	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase IV
Title	Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
Status	Completed
Sponsor	Vitreo-Retinal Associates, Michigan
NCT03105609	Click to show the Detail
Indication	Macular Degeneration; Choroidal Neovascularization
Phase	.
Title	Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging
Status	Terminated
Sponsor	Center for Eye Research Australia
NCT03115255	Click to show the Detail
Indication	Infant, Premature, Diseases
Phase	Not Applicable
Title	Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab
Status	Completed
Sponsor	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
NCT03148132	Click to show the Detail
Indication	Retinopathy of Prematurity Both Eyes; Retinal Disease; Premature Birth; Eye Diseases
Phase	Phase IV
Title	VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP
Status	Completed
Sponsor	Universidad Autonoma de San Luis Potos
NCT03150589	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase III
Title	A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Status	Completed
Sponsor	Samsung Bioepis
NCT03161652	Click to show the Detail
Indication	Diabetic Macular Edema; Diabetic Retinopathy
Phase	Phase II
Title	Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema
Status	Recruiting
Sponsor	Carmen Clapp
NCT03203447	Click to show the Detail
Indication	Macular Edema; Retinal Vein Occlusion
Phase	Phase III
Title	Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
Status	Terminated
Sponsor	Clearside Biomedical Inc
NCT03211234	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase II
Title	Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis Compared to Lucentis Monotherapy in Wet Age-related Macular Degeneration Subjects
Status	Completed
Sponsor	Santen Inc
NCT03261635	Click to show the Detail
Indication	Macular Edema
Phase	Phase IV
Title	Ranibizumab Plus Indomethacin
Status	Completed
Sponsor	Universit degli Studi di Brescia
NCT03312283	Click to show the Detail
Indication	Wet Age-related Macular Degeneration
Phase	Phase I
Title	Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis in Patients With Wet AMD
Status	Completed
Sponsor	Qilu Pharmaceutical
NCT03334513	Click to show the Detail
Indication	Retinopathy of Prematurity
Phase	.
Title	Refractive Error and Biometry in Retinopathy of Prematurity
Status	Completed
Sponsor	San Ni Chen
NCT03345082	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase II
Title	A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
Status	Completed
Sponsor	Opthea Limited
NCT03345667	Click to show the Detail
Indication	Retinopathy; Diabetic
Phase	.
Title	Assessment of Color Vision in Diabetic Patients
Status	Completed
Sponsor	Instituto de Olhos de Goiania
NCT03362190	Click to show the Detail
Indication	Wet Age-related Macular Degeneration
Phase	Phase II
Title	ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
Status	Completed
Sponsor	Ophthotech Corporation
NCT03385382	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	.
Title	Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema
Status	Completed
Sponsor	G. d'Annunzio University
NCT03393767	Click to show the Detail
Indication	Choroidal Neovascularization; Age Related Macular Degeneration
Phase	Phase IV
Title	Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD
Status	Completed
Sponsor	Vista Klinik
NCT03409250	Click to show the Detail
Indication	Choroidal Neovascularization; Age Related Macular Degeneration
Phase	Phase IV
Title	SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
Status	Completed
Sponsor	Vista Klinik
NCT03423823	Click to show the Detail
Indication	Wet Age-related Macular Degeneration
Phase	Phase II
Title	Ziv-aflibercept Efficacy in Better Regulating AMD
Status	Completed
Sponsor	Kapil Kapoor
NCT03452657	Click to show the Detail
Indication	Diabetic Retinopathy; Ranibizumab
Phase	Phase III
Title	Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)
Status	Unknown
Sponsor	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT03458923	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase IV
Title	Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema.
Status	Unknown
Sponsor	Cairo University
NCT03459144	Click to show the Detail
Indication	Polypoidal Choroidal Vasculopathy
Phase	Not Applicable
Title	Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen
Status	Completed
Sponsor	Sun Yat-sen University
NCT03495765	Click to show the Detail
Indication	Diabetic Macular Oedema
Phase	Phase III
Title	To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus
Status	Completed
Sponsor	Marsden Eye Specialists
NCT03499223	Click to show the Detail
Indication	Diabetes Mellitus; Diabetic Retinopathy; Macular Edema
Phase	Phase II
Title	A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)
Status	Completed
Sponsor	Oxurion
NCT03590444	Click to show the Detail
Indication	Diabetic Retinal Edema
Phase	Phase IV
Title	Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser
Status	Completed
Sponsor	Hospital Hietzing
NCT03609996	Click to show the Detail
Indication	Proliferative Diabetic Retinopathy
Phase	.
Title	Retrospective Review of Proliferative Diabetic Retinopathy Patients
Status	Unknown
Sponsor	Elman Retina Group
NCT03677934	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase III
Title	A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration
Status	Completed
Sponsor	Hoffmann-La Roche
NCT03683251	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase III
Title	Extension Study for the Port Delivery System With Ranibizumab (Portal)
Status	Recruiting
Sponsor	Hoffmann-La Roche
NCT03690947	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase IV
Title	Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME
Status	Recruiting
Sponsor	Beijing Hospital
NCT03709745	Click to show the Detail
Indication	Branch Retinal Vein Occlusion With Macular Edema
Phase	Phase IV
Title	Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion
Status	Recruiting
Sponsor	St. Erik Eye Hospital
NCT03725501	Click to show the Detail
Indication	Age-related Macular Degeneration
Phase	Phase II
Title	Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD
Status	Enrolling by invitation
Sponsor	AngioLab Inc
NCT03759860	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase IV
Title	Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema
Status	Unknown
Sponsor	LUTRONIC Corporation
NCT03763227	Click to show the Detail
Indication	Retinal Dystrophies
Phase	Phase II
Title	Intravitreal Ranibizumab (Lucentis) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy
Status	Completed
Sponsor	Sultan Qaboos University
NCT03784443	Click to show the Detail
Indication	Diabetic Macular Edema; Diabetes
Phase	Phase II; Phase III
Title	Combined Ranibizumab and Iluvien for Diabetic Macular Oedema
Status	Withdrawn
Sponsor	Imperial College London
NCT03805100	Click to show the Detail
Indication	Macular Degeneration
Phase	Phase III
Title	Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis in Patients With nAMD
Status	Active, not recruiting
Sponsor	Xbrane Biopharma AB
NCT03832179	Click to show the Detail
Indication	Diabetic Macular Edema; Cataract
Phase	Phase IV
Title	Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
Status	Recruiting
Sponsor	Bay Area Retina Associates
NCT03834753	Click to show the Detail
Indication	Age-related Macular Degeneration; Neovascular Age-related Macular Degeneration; Wet Macular Degeneration
Phase	Phase III
Title	A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Status	Active, not recruiting
Sponsor	Outlook Therapeutics
NCT03844074	Click to show the Detail
Indication	Age-related Macular Degeneration; Neovascular Age-related Macular Degeneration; Wet Macular Degeneration
Phase	Phase III
Title	A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Status	Completed
Sponsor	Outlook Therapeutics
NCT03904056	Click to show the Detail
Indication	Diabetic Retinopathy
Phase	Not Applicable
Title	ETDRS PRP With IVR Versus Retinal Photocoagulation Targeted to Ischemic Retina With IVR for the Treatment of PDR
Status	Completed
Sponsor	Sao Paulo State University
NCT03927690	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase II
Title	Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
Status	Recruiting
Sponsor	Novartis Pharmaceuticals
NCT03944070	Click to show the Detail
Indication	Wet Macular Degeneration; Cataract Extraction
Phase	Not Applicable
Title	Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery
Status	Unknown
Sponsor	Ophthalmica Eye Institute
NCT03963596	Click to show the Detail
Indication	Pathologic Myopia
Phase	Not Applicable
Title	Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Myopia
Status	Recruiting
Sponsor	The Filatov Institute of Eye Diseases and Tissue Therapy
NCT03973138	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase I; Phase II
Title	Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With Ranibizumab
Status	Unknown
Sponsor	Sun Yat-sen University
NCT03975088	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Not Applicable
Title	Sub-macular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema
Status	Completed
Sponsor	University of Alexandria
NCT03999125	Click to show the Detail
Indication	Clinically Significant Macular Edema Due to Diabetes Mellitus
Phase	Phase IV
Title	Anti-VEGF Therapy Versus Dexamethasone Implant for DME
Status	Not Recruiting
Sponsor	Sudhalkar Eye Hospital
NCT04018833	Click to show the Detail
Indication	Diabetic Macular Edema; Diabetic Retinopathy
Phase	.
Title	Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema
Status	Completed
Sponsor	Bernardete Pessoa MD
NCT04062370	Click to show the Detail
Indication	Retinal Vein Occlusion; Treatment; Photocoagulation Burn to Retina; Ranibizumab
Phase	Phase IV
Title	Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion
Status	Not Recruiting
Sponsor	Sun Yat-sen University
NCT04063358	Click to show the Detail
Indication	Diabetic Macular Edema; Cataract
Phase	Phase III
Title	Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery
Status	Recruiting
Sponsor	Second Military Medical University
NCT04075136	Click to show the Detail
Indication	Exudative Age Related Macular Degeneration
Phase	Phase IV
Title	Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
Status	Not Recruiting
Sponsor	Wake Forest University Health Sciences
NCT04087746	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase IV
Title	Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)
Status	Completed
Sponsor	Minia University
NCT04089605	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase IV
Title	Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema
Status	Completed
Sponsor	Far Eastern Memorial Hospital
NCT04108156	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Phase III
Title	This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab
Status	Active, not recruiting
Sponsor	Hoffmann-La Roche
NCT04119219	Click to show the Detail
Indication	Angioid Streaks of Macula
Phase	Not Applicable
Title	Antiangiogenic Therapy of CNV Associated With Angioid Streaks
Status	Recruiting
Sponsor	The Filatov Institute of Eye Diseases and Tissue Therapy
NCT04140448	Click to show the Detail
Indication	Retinal Vein Occlusion; Macular Edema
Phase	.
Title	Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion
Status	Recruiting
Sponsor	Renmin Hospital of Wuhan University
NCT04186702	Click to show the Detail
Indication	Diabetes Mellitus, With Complications
Phase	Not Applicable
Title	New Concepts in Diabetic Macular Edema (DME)
Status	Completed
Sponsor	Ain Shams University
NCT04245072	Click to show the Detail
Indication	Chorioretinitis
Phase	Not Applicable
Title	Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis
Status	Recruiting
Sponsor	The Filatov Institute of Eye Diseases and Tissue Therapy
NCT04310631	Click to show the Detail
Indication	Coats Disease
Phase	.
Title	Evaluation of Retinal and Vascular Features in Coats Disease After Intravitreal Injections of Ranibizumab
Status	Completed
Sponsor	Federico II University
NCT04332133	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	Not Applicable
Title	Outcomes of Subthreshold Laser Versus Intravitreal Injection of Ranibizumab in Diabetic Macular Edema
Status	Completed
Sponsor	Minia University
NCT04377295	Click to show the Detail
Indication	Radiation Maculopathy
Phase	.
Title	Evaluation of Retinal and Vascular Features in Radiation Maculopathy After Intravitreal Injections of Ranibizumab
Status	Completed
Sponsor	Federico II University
NCT04387604	Click to show the Detail
Indication	Diabetic Macular Edema
Phase	.
Title	Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema
Status	Completed
Sponsor	Centro Hospitalar do Porto
NCT04444492	Click to show the Detail
Indication	Central Retinal Vein Occlusion With Macular Edema
Phase	Phase III
Title	Combination of Ranibizumab and Targeted Laser Photocoagulation
Status	Recruiting
Sponsor	University of Leipzig
NCT04460001	Click to show the Detail
Indication	Ophthalmopathy
Phase	Phase II; Phase III
Title	Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)
Status	Recruiting
Sponsor	Assiut University
NCT04464694	Click to show the Detail
Indication	Proliferative Diabetic Retinopathy; Diabetic Macular Edema
Phase	Phase IV
Title	Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema
Status	Not Recruiting
Sponsor	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
NCT04503551	Click to show the Detail
Indication	Diabetic Retinopathy
Phase	Phase III
Title	A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
Status	Recruiting
Sponsor	Hoffmann-La Roche
NCT04514653	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase II
Title	RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Status	Recruiting
Sponsor	Regenxbio
NCT04537065	Click to show the Detail
Indication	Retinopathy of Prematurity
Phase	.
Title	Long Term Outcome of Intravitreal Ranibizumab for ROP
Status	Completed
Sponsor	Ameera Gamal Abdelhameed
NCT04539106	Click to show the Detail
Indication	Retinopathy of Prematurity
Phase	.
Title	Intravitreal Ranibizumab in Recurrent ROP
Status	Completed
Sponsor	Ameera Gamal Abdelhameed
NCT04601675	Click to show the Detail
Indication	Macular Edema
Phase	Not Applicable
Title	Diabetic Macular Edema (DME) Treatment With Ranibizumab and Dexamethasone or Ranibizumab Only.
Status	Not Recruiting
Sponsor	He Eye Hospital
NCT04657289	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration (nAMD)
Phase	Phase III
Title	A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
Status	Recruiting
Sponsor	Hoffmann-La Roche
NCT04662944	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	.
Title	A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
Status	Recruiting
Sponsor	Novartis Pharmaceuticals
NCT04667039	Click to show the Detail
Indication	Age Related Macular Degeneration (ARMD)
Phase	Phase III
Title	Efficacy, Safety, pharmacokinetis, Immunogenicity of GNR-067 and Lucentis
Status	Not Recruiting
Sponsor	AO GENERIUM
NCT04667897	Click to show the Detail
Indication	Branch Retinal Vein Occlusion
Phase	Phase II
Title	601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
Status	Not Recruiting
Sponsor	Sunshine Guojian Pharmaceutical (Shanghai)
NCT04667910	Click to show the Detail
Indication	Central Retinal Vein Occlusion
Phase	Phase II
Title	601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)
Status	Not Recruiting
Sponsor	Sunshine Guojian Pharmaceutical (Shanghai)
NCT04685369	Click to show the Detail
Indication	Wet Age-related Macular Degeneration
Phase	.
Title	Effectiveness of Anti-VEGF Treatments in Wet AMD in Active Smokers
Status	Recruiting
Sponsor	Brugmann University Hospital
NCT04690556	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase III
Title	Study to Compare Efficacy and Safety of LUBT010 and Lucentis in Patients With Neovascular AMD
Status	Recruiting
Sponsor	Lupin Ltd
NCT04698850	Click to show the Detail
Indication	Wet Macular Degeneration
Phase	Phase IV
Title	Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation
Status	Not Recruiting
Sponsor	Faculty Hospital Kralovske Vinohrady
NCT04704921	Click to show the Detail
Indication	Wet Age-related Macular Degeneration
Phase	Phase II; Phase III
Title	Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD
Status	Recruiting
Sponsor	Regenxbio
NCT04714242	Click to show the Detail
Indication	Polypoidal Choroidal Vasculopathy
Phase	.
Title	OCTA and Polypoidal Choroidal Vasculopathy
Status	Completed
Sponsor	Federico II University
NCT04740671	Click to show the Detail
Indication	Age Related Macular Degeneration
Phase	Phase III
Title	A Phase III Two-part Study of the Efficacy and Safety of HLX04-O in Subjects With Wet Age-related Macular Degeneration
Status	Recruiting
Sponsor	Shanghai Henlius Biotech
NCT04757610	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase III
Title	OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
Status	Recruiting
Sponsor	Opthea Limited
NCT04847895	Click to show the Detail
Indication	Neovascular (Wet) Age-related Macular Degeneration
Phase	.
Title	Observation of Treatment Patterns With Lucentis in Real-life Conditions in All Approved Indications
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT04853251	Click to show the Detail
Indication	Neovascular Age-related Macular Degeneration
Phase	Phase III
Title	A Study Of The Efficacy And Safety Of The Port Delivery System With Ranibizumab In Patients With Neovascular Age-Related Macular Degeneration Previously Treated With Intravitreal Agents Other Than Ranibizumab
Status	Not Recruiting
Sponsor	Genentech Inc
NCT04857177	Click to show the Detail
Indication	Neovascular (Wet) Age Related Macular Degeneration
Phase	Phase III
Title	A Study To Evaluate CKD-701 and Lucentis in Patients With Neovascular(Wet) Age Related Macular Degeneration
Status	Completed
Sponsor	Chong Kun Dang Pharmaceutical
NCT04878835	Click to show the Detail
Indication	Patients With Primary Nasal Pterygium
Phase	Phase I
Title	Effects of Ranibizumab in Primary Pterygium Surgery
Status	Completed
Sponsor	Universiti Sains Malaysia
NCT04884399	Click to show the Detail
Indication	Wet Age-related Macular Degeneration
Phase	Phase I
Title	Phase I Study to Compare CMAB818 Injection and Lucentis in Patients With Wet AMD
Status	Recruiting
Sponsor	Shanghai Biomabs Pharmaceutical
NCT04922151	Click to show the Detail
Indication	Pathological Myopic Choroidal Neovascularization
Phase	Phase II
Title	601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)
Status	Recruiting
Sponsor	Sunshine Guojian Pharmaceutical (Shanghai)
NCT04982484	Click to show the Detail
Indication	Ophthalmopathy; Wet Macular Degeneration
Phase	.
Title	Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment
Status	Completed
Sponsor	Centre Hospitalier Regional Metz-Thionville
NCT05033106	Click to show the Detail
Indication	Retinopathy of Prematurity Both Eyes
Phase	Phase III
Title	Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity
Status	Unknown status
Sponsor	Zagazig University
NCT05304949	Click to show the Detail
Indication	Retinopathy of Prematurity
Phase	Observational
Title	Regulatory PMS Study for Lucentis in Patients With Retinopathy of Prematurity
Status	Recruiting
Sponsor	Novartis Pharmaceuticals
NCT05576792	Click to show the Detail
Indication	Retinopathy of Prematurity
Phase	Observational
Title	A 24-week Study Evaluating the Effectiveness and Safety of Lucentis? 0.2mg in Retinopathy of Prematurity Participants in China
Status	Recruiting
Sponsor	Novartis Pharmaceuticals
NCT05701124	Click to show the Detail
Indication	Retina Disease; Retinopathy of Prematurity; Ranibizumab
Phase	Phase III
Title	Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity
Status	Completed
Sponsor	Zagazig University
NCT06234514	Click to show the Detail
Indication	Macular Cystoid Edema
Phase	Phase IV
Title	Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab
Status	Recruiting
Sponsor	Dongyang People's Hospital

References

Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2018 Oct 1;136(10):1138-1148.